Investigating the safety and effects of Lorbrena in lung cancer patients
Special Investigation for LORBRENA Tablets
This study is testing how safe and effective Lorbrena is for people with non-small cell lung cancer and looking at its effects on the brain and liver when taken with certain other medications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 683 (estimated) |
| Ages | 0 Years and up |
| Sex | All |
| Sponsor | Pfizer Industry-sponsored |
| Locations | 1 site (Tokyo) |
| Trial ID | NCT03844464 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the safety and efficacy of Lorbrena in patients diagnosed with non-small cell lung cancer who have received this medication. It focuses on understanding factors that may influence the onset of central nervous system disorders and the impact of Lorbrena when used alongside CYP3A inducers on liver function. The study will gather data from patients who have been administered Lorbrena to assess these outcomes in a real-world setting.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with non-small cell lung cancer who have been treated with Lorbrena.
Not a fit: Patients who have not received Lorbrena or those with conditions unrelated to lung cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the safe use of Lorbrena and its interactions, improving treatment protocols for lung cancer patients.
How similar studies have performed: While this study is observational and focuses on post-marketing use, similar studies have shown that monitoring real-world drug effects can yield important safety and efficacy data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All administered patients Exclusion Criteria: * Nothing
Where this trial is running
Tokyo
- 3-22-7, Yoyogi, Shibuya-ku — Tokyo, Japan (Recruiting)
Study contacts
- Study coordinator: Pfizer CT.gov Call Center
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
- Phone: 1-800-718-1021
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.